Recent advances in the structure-based and ligand-based design of IKKβ inhibitors as anti-inflammation and anti-cancer agents

Current Medicinal Chemistry

Volumn 21, Issue 34, 2014, Pages 3893-3917

  Huang, Jing Jie ^a   Chu, Hong Xi ^a   Jiang, Zheng Yu ^a   Zhang, Xiao Jin ^a   Sun, Hao Peng ^a   You, Qi Dong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

ATP competitive inhibitors; Binding mode; IKK inhibitors; I B kinase (IKK); NF B; Protein protein interaction inhibitors; Transcription factor

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; ADENOSINE TRIPHOSPHATE; ANILINOPYRIMIDINE INHIBITOR; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; AZAINDOLE DERIVATIVE; BETA CARBOLINE INHIBITOR; CHS 828; DIARYLBENZAMIDE INHIBITOR; I KAPPA B KINASE BETA; I KAPPA B KINASE BETA INHIBITOR; IMD 1041; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; ISOQUINOLINE INHIBITOR; OLIGONUCLEOTIDE; PHENYLPYRIDINE INHIBITOR; TEGLARINAD CHLORIDE; THIENOPYRIDINE INHIBITOR; THIOPHENECARBOXAMIDE INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; HUMAN; MOLECULAR DOCKING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 84919634243     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140815130205     Document Type: Article

References (101)

1. Sen, R.; Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46(5), 705-716.
2. Sen, R.; Baltimore, D. Inducibility of κ immunoglobulin enhancerbinding protein NF-κB by a posttranslational mechanism. Cell, 1986, 47(6), 921-928.
3. Tak, P. P.; Firestein, G. S. NF-κB: a key role in inflammatory diseases. J. Clin. Invest., 2001, 107(1), 7-11.
4. Karin, M. The IκB kinase (IKK) complex as a critical regulator of immune responses. Int. Cong. Series, 2005, 1285, 97-103.
5. Baldwin, A. S. Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer. Immunol. Rev., 2012, 246(1), 327-345.
6. Rottenberg, S.; Schmuckli-Maurer, J.; Grimm, S.; Heussler, V. T.; Dobbelaere, D. A. E. Characterization of the bovine IκB kinases (IKK) α and IKKβ, the regulatory subunit NEMO and their substrate IkBα. Gene, 2002, 299, 293-300.
7. Baxter, A.; Brough, S.; Cooper, A.; Floettmann, E.; Foster, S.; Harding, C.; Kettle, J.; McInally, T.; Martin, C.; Mobbs, M. Hit-tolead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(11), 2817-2822.
8. Kundu, J.; Surh, Y. Inflammation: Gearing the journey to cancer. Mutat. Res-Rev. Mutat., 2008, 659(1-2), 15-30.
9. Greten, F. The IKK/NF-κB activation pathway-a target for prevention and treatment of cancer. Cancer Lett., 2004, 206(2), 193-199.
10. Karin, M. Nuclear factor-κB in cancer development and progression. Nature, 2006, 441, 431-436.
11. Chen, J.; McKay, R. M.; Parada, L. F. Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells. Cell, 2012, 149(1), 36-47.
12. Sun, B.; Karin, M. NF-κB signaling, liver disease and hepatoprotective agentsNF-κB signaling, liver disease and hepatoprotective agents. Oncogene, 2008, 27, 6228-6244.
13. Luedde, T.; Schwabe, R. F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastro. Hepat., 2010, 8, 108-118.
14. Ben-Neriah, Y.; Karin, M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol., 2011, 12(8), 715-723.
15. Wu, L.; Shao, L.; An, N.; Wang, J.; Pazhanisamy, S.; Feng, W.; Hauer-Jensen, M.; Miyamoto, S.; Zhou, D. IKKβ Regulates the Repair of DNA Double-Strand Breaks Induced by Ionizing Radiation in MCF-7 Breast Cancer Cells. PLoS One, 2011, 6(4), e18447.
16. Sakamoto, K.; Hikiba, Y.; Nakagawa, H.; Hirata, Y.; Hayakawa, Y.; Kinoshita, H.; Nakata, W.; Sakitani, K.; Takahashi, R.; Akanuma, M.; Kamata, H.; Maeda, S. Promotion of DNA repair by nuclear IKKβ phosphorylation of ATM in response to genotoxic stimuli. Oncogene, 2012.
17. Tilstra, J. S.; Robinson, A. R.; Wang, J.; Gregg, S. Q.; Clauson, C. L.; Reay, D. P.; Nasto, L. A.; St Croix, C. M.; Usas, A.; Vo, N.; Huard, J.; Clemens, P. R.; Stolz, D. B.; Guttridge, D. C.; Watkins, S. C.; Garinis, G. A.; Wang, Y.; Niedernhofer, L. J.; Robbins, P. D. NF-κB inhibition delays DNA damage-induced senescence and aging in mice. J. Clin. Invest., 2012, 122(7), 2601-2612.
18. Schmid, J. A.; Birbach, A. IκB kinase β (IKKβ/IKK2/IKBKB)-A key molecule in signaling to the transcription factor NF-κB. Cytokine Growth Factor Rev., 2008, 19(2), 157-165.
19. Amit, S.; Ben-Neriah, Y. NF-κB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin. Cancer Biol., 2003, 13(1), 15-28.
20. Malek, S.; Chen, Y.; Huxford, T.; Ghosh, G. Ikappa Bbeta, but not Ikappa Balpha, functions as a classical cytoplasmic inhibitor of NFkappa B dimers by masking both NF-kappa B nuclear localization sequences in resting cells. J. Biol. Chem., 2001, 276, 45225-45235.
21. Johnson, C.; Antwerp, D. V.; Hope, T. An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IkappaBalpha. EMBO J., 1999, 18, 6682-6693.
22. Liu, F.; Xia, Y.; Parker, A. S.; Verma, I. M. IKK biology. Immunol. Rev., 2012, 246(1), 239-253.
23. Chiu, Y.-H.; Zhao, M.; Chen, Z. J. Ubiquitin in NF-κB Signaling. Chem. Rev., 2009, 109, 1549-1560.
24. Chariot, A. The NF-κB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol., 2009, 19(8), 404-413.
25. Xu, G.; Lo, Y. C.; Li, Q.; Napolitano, G.; Wu, X.; Jiang, X.; Dreano, M.; Karin, M.; Wu, H. Crystal structure of inhibitor of kappaB kinase beta. Nature, 2011, 472(7343), 325-330.
26. Scheidereit, C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene, 2006, 25(51), 6685-6705.
27. Binderup, E.; Björkling, F.; Hjarnaa, P. V.; Latini, S.; Baltzer, B.; Carlsen, M.; Binderup, L. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorg. Med. Chem. Lett., 2005, 15(10), 2491-2494.
28. Nagarajan, S.; Choo, H.; Cho, Y. S.; Oh, K.-S.; Lee, B. H.; Shin, K. J.; Pae, A. N. IKKβ inhibitors identification part II: Ligand and structure-based virtual screening. Bioorg. Med. Chem., 2010, 18(11), 3951-3960.
29. Suzuki, J.-I.; Ogawa, M.; Muto, S.; Itai, A.; Isobe, M.; Hirata, Y.; Nagai, R. Novel IkB kinase inhibitors for treatment of nuclear factor-κB-related diseases. Expert Opin. Inv. Drug, 2011, 20(3), 395-405.
30. Hjarnaa, P.-J. V.; Jonsson, E.; Latini, S.; Dhar, S.; Larsson, R.; Bramm, E.; Skov, T.; Binderup, L. CHS 828, a Novel Pyridyl Cyanoguanidine with Potent Antitumor Activity in Vitro and in Vivo. Cancer Res., 1999, 59, 5751-5757.
31. Olsen, L. S.j.; Hjarnaa, P.-J. V.; Latini, S.; Holm, P. K.; Larsson, R.; Bramm, E.; Binderup, L.; Madsen, M. W. Anticancer agent CHS 828 suppresses nuclear factor-κB activity in cancer cells through downregulation of IKK activity. Int. J. Cancer, 2004, 111(2), 198-205.
32. Hovstadius, P.; Larsson, R.; Jonsson, E.; Skov, T.; Kissmeyer, A.-M.; Krasilnikoff, K.; Bergh, J.; Karlsson, M. O.; Lonnebo, A.; Ahlgren, J. A Phase I Study of CHS 828 in Patients with Solid Tumor Malignancy. Clin. Cancer Res., 2002, 8, 2843-2850.
33. Enid, A.-D. M.; Denise, H. D.; A. Use of PKC-iota inhibitors for the treatment of breast cancer. WO2012037553, 2012.
34. Liu, L.; Zhou, H.; Li, T.; Wong, K. W.; Jiang, Z. H. Dihydromyricetin as an IKK-beta inhibitor used for treatment of arthritis, cancer and autoimmune conditions, and other diseases or disorders. US20120053235, 2012.
35. Zuo, Y.; Huang, J.; Zhou, B.; Wang, S.; Shao, W.; Zhu, C.; Lin, L.; Wen, G.; Wang, H.; Du, J.; Bu, X. Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling. Eur. J. Med. Chem., 2012, 55, 346-357.
36. Wu, J. H.; Batist, G.; Zhou, J. M.; Geng, G. Y.; Lin, R. T. Hybridionone and curcumin molecules as anticancer agents. US20110230488, 2011.
37. Karin, M.; Kapahi, P. Methods for identifying and using IKK inhibitors. US20090054524, 2009.
38. Murata, T.; Shimada, M.; Sakakibara, S.; Yoshino, T.; Kadono, H.; Masuda, T.; Shimazaki, M.; Shintani, T.; Fuchikami, K.; Sakai, K.; Inbe, H.; Takeshita, K.; Niki, T.; Umeda, M.; Bacon, K. B.; Ziegelbauer, K. B.; Lowinger, T. B. Discovery of novel and selective IKKbeta serine-threonine protein kinase inhibitors. Part 1. Bioorg. Med. Chem. Lett., 2003, 13(5), 913-918.
39. Murata, T.; Shimada, M.; Kadono, H.; Sakakibara, S.; Yoshino, T.; Masuda, T.; Shimazaki, M.; Shintani, T.; Fuchikami, K.; Bacon, K. B.; Ziegelbauer, K. B.; Lowinger, T. B. Synthesis and structureactivity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity. Bioorg. Med. Chem. Lett., 2004, 14(15), 4013-4017.
40. Murata, T.; Shimada, M.; Sakakibara, S.; Yoshino, T.; Masuda, T.; Shintani, T.; Sato, H.; Koriyama, Y.; Fukushima, K.; Nunami, N. Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg. Med. Chem. Lett., 2004, 14(15), 4019-4022.
41. Bingham, A. H.; Davenport, R. J.; Gowers, L.; Knight, R. L.; Lowe, C.; Owen, D. A.; Parry, D. M.; Pitt, W. R. A novel series of potent and selective IKK2 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(2), 409-412.
42. Bingham, A. H.; Davenport, R. J.; Fosbeary, R.; Gowers, L.; Knight, R. L.; Lowe, C.; Owen, D. A.; Parry, D. M.; Pitt, W. R. Synthesis and structure-activity relationship of aminopyrimidine IKK2 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(12), 3622-3627.
43. Kim, S.; Jung, J. K.; Lee, H. S.; Kim, Y.; Kim, J.; Choi, K.; Baek, D. J.; Moon, B.; Oh, K. S.; Lee, B. H.; Shin, K. J.; Pae, A. N.; Nam, G.; Roh, E. J.; Cho, Y. S.; Choo, H. Discovery of piperidinyl amino pyrimidine derivatives as IKK-2 inhibitors. Bioorg. Med. Chem. Lett., 2011, 21(10), 3002-3006.
44. Waelchli, R.; Bollbuck, B.; Bruns, C.; Buhl, T.; Eder, J.; Feifel, R.; Hersperger, R.; Janser, P.; Revesz, L.; Zerwes, H. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK. Bioorg. Med. Chem. Lett., 2006, 16(1), 108-112.
45. Didier, B.; Monsif, B.; Pierre, C.; Maria, M.-P.; Serge, M.; Jean-Flaubert, N.; Jacob-Alsboek, O.; Bernard, T.; Jean, W. Novel N, N'-2, 4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors. TW200900068, 2009.
46. Didier, B.; Monsif, B.; Pierre, C.; Serge, M.; Jean-Flaubert, N.; Jean, W. Novel 2-anilino-4-heteroaryl-pyrimidine derivatives, their preparation, as medicaments, pharmaceutical compositions and in particular as IKK inhibitors. TW200900069, 2009.
47. Monsif, B.; Bernard, T. Novel N, N'-2, 4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and in particular as IKK inhibitors. TW200916457, 2009.
48. Monsif, B.; Pierre, C.; Sherri, D.; Regine, F.; Jean-Flaubert, N.; Bernard, T.; Jean, W.; Maria, M.-P.; Jacob-Alsboek, O. Novel phenyl (4-phenylpyrimidin-2-yl) amine derivatives, their preparation, as medicaments, pharmaceutical compositions and in particular as IKK inhibitors. TW200848048, 2008.
49. K, S. M.; Jeffery, M.; Hyung, Y. W.; Stephen, N.; Dale, R. Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith. WO2009089042, 2009.
50. Philip, C. Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma. WO2009030890, 2009.
51. Robert, P. T.; Karl, N. G.; Richard, S. M. Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, Processes for their preparation, and pharmaceutical compositions containing them. WO2012010826, 2012.
52. Moffat, D. F. C.; Davies, S. J.; Charlton, M. H.; Hirst, S. C.; Onions, S. T.; Williams, J. G. Inhibitors of IKK-beta serine-threonine protin kinase. US20100069473, 2010.
53. Faull, A. W.; Johnstone, C.; Morley, A. D.; Poyser, J. P. Thiophenecarboxamide derivatives and their use as inhibitors of the enzyme IKK-2. US20100029754, 2010.
54. Huang, J. J.; Wu, X. W.; Jia, J. M.; Guo, X. K.; Xue, X.; Jiang, Z. Y.; Zhang, S. L.; Zhang, X. J.; Sun, H. P.; You, Q. D. Novel IKKbeta inhibitors discovery based on the co-crystal structure by using bindingconformation-based and ligand-based method. Eur. J. Med. Chem., 2013, 63, 269-278.
55. Lauria, A.; Ippolito, M.; Fazzari, M.; Tutone, M.; Di Blasi, F.; Mingoia, F.; Almerico, A. M. IKK-β inhibitors: An analysis of drug-receptor interaction by using Molecular Docking and Pharmacophore 3D-QSAR approaches. J. Mol. Graphics Modell., 2010, 29(1), 72-81.
56. Bonafoux, D.; Bonar, S.; Christine, L.; Clare, M.; Donnelly, A.; Guzova, J.; Kishore, N.; Lennon, P.; Libby, A.; Mathialagan, S. Inhibition of IKK-2 by 2-[(aminocarbonyl) amino]-5-acetylenyl-3-thiophenecarboxamides. Bioorg. Med. Chem. Lett., 2005, 15(11), 2870-2875.
57. Liddle, J.; Bamborough, P.; Barker, M. D.; Campos, S.; Cousins, R. P. C.; Cutler, G. J.; Hobbs, H.; Holmes, D. S.; Ioannou, C.; Mellor, G. W. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(9), 2504-2508.
58. Miller, D. D.; Bamborough, P.; Christopher, J. A.; Baldwin, I. R.; Champigny, A. C.; Cutler, G. J.; Kerns, J. K.; Longstaff, T.; Mellor, G. W.; Morey, J. V.; Morse, M. A.; Nie, H.; Rumsey, W. L.; Taggart, J. J. 3, 5-Disubstituted-indole-7-carboxamides: The discovery of a novel series of potent, selective inhibitors of IKK-β. Bioorg. Med. Chem. Lett., 2011, 21(8), 2255-2258.
59. Boehm, J. C.; Busch-Petersen, J.; Fu, W.; Jin, Q.; Kerns, J. K.; Li, H.; Lin, G.; Lin, X.; Neipp, C. E. Indole carboxamides as IKK2 inhibitors. US20120040958, 2012.
60. Deng, J.; Kerns, J. K.; Jin, Q.; Lin, G.; Lin, X.; Lindenmuth, M.; Neipp, C.; Nie, H.; Thomas, S. M.; Widdowson, K. L. Chemical compounds. US20120035164, 2012.
61. Enomoto, H.; Kawashima, K.; Kudou, K.; Yamamoto, M.; Murai, M.; Inaba, T.; Ishizaka, N. Novel indole derivative having IκB kinase beta inhibitory activity. US20100041628, 2010.
62. Kawashima, K.; Enomoto, H.; Yamamoto, M.; Murai, M. Novel indole derivatives having, carbamoyl group, ureido group and substituted oxy group. US20110124668, 2011.
63. Christopher, J. A.; Avitabile, B. G.; Bamborough, P.; Champigny, A. C.; Cutler, G. J.; Dyos, S. L.; Grace, K. G.; Kerns, J. K.; Kitson, J. D.; Mellor, G. W. The discovery of 2-amino-3, 5-diarylbenzamide inhibitors of IKK-α and IKK-β kinases. Bioorg. Med. Chem. Lett., 2007, 17(14), 3972-3977.
64. Morwick, T.; Berry, A.; Brickwood, J.; Cardozo, M.; Catron, K.; De Turi, M.; Emeigh, J.; Homon, C.; Hrapchak, M.; Jacober, S.; Jakes, S.; Kaplita, P.; Kelly, T. A.; Ksiazek, J.; Liuzzi, M.; Magolda, R.; Mao, C.; Marshall, D.; McNeil, D.; Prokopowicz, A.; Sarko, C.; Scouten, E.; Sledziona, C.; Sun, S.; Watrous, J.; Wu, J. P.; Cywin, C. L. Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies. J. Med. Chem., 2006, 49(10), 2898-2908.
65. Cywin, C. L.; Chen, Z.; Fleck, R. W.; Hao, M.; Hickey, E.; Liu, W.; Marshall, D. R.; Nemoto, P.; Sorcek, R. J.; Sun, S.; Wu, J.; Morwick, T.; Emeigh, J. Substitued 3-amino-thieno[2, 3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses. US6964956, 2005.
66. David, G. J.; J., S. R.; Robert, T. M.; Roush, Y. E. R. Substitued 3-amino-thieno[2, 3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses. TW200815457, 2008.
67. Christopher, J. A.; Bamborough, P.; Alder, C.; Campbell, A.; Cutler, G. J.; Down, K.; Hamadi, A. M.; Jolly, A. M.; Kerns, J. K.; Lucas, F. S.; Mellor, G. W.; Miller, D. D.; Morse, M. A.; Pancholi, K. D.; Rumsey, W.; Solanke, Y. E.; Williamson, R. Discovery of 6-Aryl-7-alkoxyisoquinoline Inhibitors of IκB Kinase-β (IKK-β). J. Med. Chem., 2009, 52(9), 3098-3102.
68. Shunsuke, K.; Kenichiro, S.; Daisuke, S.; Rintaro, Y.; Katsuhiko, S. 8-substituted isoquinolin derivative and use thereof. EP2366699, 2011.
69. Castro, A. C.; Dang, L. C.; Soucy, F.; Grenier, L.; Mazdiyasni, H.; Hottelet, M.; Parent, L.; Pien, C.; Palombella, V.; Adams, J. Novel IKK inhibitors: β-carbolines. Bioorg. Med. Chem. Lett., 2003, 13(14), 2419-2422.
70. A., H. F.; Ian, C. M.; Marianne, L.; Adrian, S. C. B. Mesylate salt of an IKK inhibitor. WO2009054970, 2009.
71. A., H. F.; Ian, C. M.; Adrian, S. C. B. Salts of N-(6-chloro-9Hpyrido[3, 4-b]indole-8-yl)-4-[2-(2, 6-dimethyl-4-morpholinyl)-2-oxoethyl]-6, 6'-dimethyl-morpholinecarboxamide. WO2009054965, 2009.
72. Noha, S. M.; Atanasov, A. G.; Schuster, D.; Markt, P.; Fakhrudin, N.; Heiss, E. H.; Schrammel, O.; Rollinger, J. M.; Stuppner, H.; Dirsch, V. M. Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques. Bioorg. Med. Chem. Lett., 2011, 21(1), 577-583.
73. Nagarajan, S.; Choo, H.; Cho, Y. S.; Shin, K. J.; Oh, K.-S.; Lee, B. H.; Pae, A. N. IKK-β inhibitor identification: a multi-filter driven novel scaffold. BMC Bioinf., 2010, 11(Suppl 7), S15.
74. Avila, C. M.; Lopes, A. B.; Gonçalves, A. S.; Da Silva, L. L.; Romeiro, N. C.; Miranda, A. L. P.; Sant'Anna, C. M. R.; Barreiro, E. J.; Fraga, C. A. M. Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IκB kinase-β. Eur. J. Med. Chem., 2011, 46(4), 1245-1253.
75. Burke, J. R. BMS-345541 Is a Highly Selective Inhibitor of Ikappa B Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-kappa B-dependent Transcription in Mice. J. Biol. Chem., 2002, 278(3), 1450-1456.
76. Kempson, J.; Spergel, S. H.; Guo, J.; Quesnelle, C.; Gill, P.; Belanger, D.; Dyckman, A. J.; Li, T.; Watterson, S. H.; Langevine, C. M.; Das, J.; Moquin, R. V.; Furch, J. A.; Marinier, A.; Dodier, M.; Martel, A.; Nirschl, D.; Van Kirk, K.; Burke, J. R.; Pattoli, M. A.; Gillooly, K.; McIntyre, K. W.; Chen, L.; Yang, Z.; Marathe, P. H.; Wang-Iverson, D.; Dodd, J. H.; McKinnon, M.; Barrish, J. C.; Pitts, W. J. Novel Tricyclic Inhibitors of IκB Kinase. J. Med. Chem., 2009, 52(7), 1994-2005.
77. Dyckman, A. J.; Langevine, C. M.; Quesnelle, C.; Kempson, J.; Guo, J.; Gill, P.; Spergel, S. H.; Watterson, S. H.; Li, T.; Nirschl, D. S.; Gillooly, K. M.; Pattoli, M. A.; McIntyre, K. W.; Chen, L.; McKinnon, M.; Dodd, J. H.; Barrish, J. C.; Burke, J. R.; Pitts, W. J. Imidazo[4, 5-d]thiazolo[5, 4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. Bioorg. Med. Chem. Lett., 2011, 21(1), 383-386.
78. Kempson, J.; Guo, J.; Das, J.; Moquin, R. V.; Spergel, S. H.; Watterson, S. H.; Langevine, C. M.; Dyckman, A. J.; Pattoli, M.; Burke, J. R. Synthesis, initial SAR and biological evaluation of 1, 6-dihydroimidazo[4, 5-d]pyrrolo[2, 3-b]pyridin-4-amine derived inhibitors of IαB kinase. Bioorg. Med. Chem. Lett., 2009, 19(10), 2646-2649.
79. Beaulieu, F.; Ouellet, C.; Ruediger, E. H.; Belema, M.; Qiu, Y.; Yang, X.; Banville, J.; Burke, J. R.; Gregor, K. R.; MacMaster, J. F.; Martel, A.; McIntyre, K. W.; Pattoli, M. A.; Zusi, F. C.; Vyas, D. Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(5), 1233-1237.
80. Luciferaseluciferase Belema, M.; Bunker, A.; Nguyen, V. N.; Beaulieu, F.; Ouellet, C.; Qiu, Y.; Zhang, Y.; Martel, A.; Burke, J. R.; McIntyre, K. W.; Pattoli, M. A.; Daloisio, C.; Gillooly, K. M.; Clarke, W. J.; Brassil, P. J.; Zusi, F. C.; Vyas, D. M. Synthesis and structure-activity relationship of imidazo (1, 2-a) thieno (3, 2-e) pyrazines as IKK-beta inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(15), 4284-4289.
81. Kempson, J.; Spergel, S. H.; Guo, J.; Quesnelle, C.; Gill, P.; Belanger, D.; Dyckman, A. J.; Li, T.; Watterson, S. H.; Langevine, C. M.; Das, J.; Moquin, R. V.; Furch, J. A.; Marinier, A.; Dodier, M.; Martel, A.; Nirschl, D.; Van Kirk, K.; Burke, J. R.; Pattoli, M. A.; Gillooly, K.; McIntyre, K. W.; Chen, L.; Yang, Z.; Marathe, P. H.; Wang-Iverson, D.; Dodd, J. H.; McKinnon, M.; Barrish, J. C.; Pitts, W. J. Novel tricyclic inhibitors of IkappaB kinase. J. Med. Chem., 2009, 52(7), 1994-2005.
82. Kempson, J.; Guo, J.; Das, J.; Moquin, R. V.; Spergel, S. H.; Watterson, S. H.; Langevine, C. M.; Dyckman, A. J.; Pattoli, M.; Burke, J. R.; Yang, X.; Gillooly, K. M.; McIntyre, K. W.; Chen, L.; Dodd, J. H.; McKinnon, M.; Barrish, J. C.; Pitts, W. J. Synthesis, initial SAR and biological evaluation of 1, 6-dihydroimidazo[4, 5-d]pyrrolo[2, 3-b]pyridin-4-amine derived inhibitors of IkappaB kinase. Bioorg. Med. Chem. Lett., 2009, 19(10), 2646-2649.
83. Watterson, S. H.; Langevine, C. M.; Van Kirk, K.; Kempson, J.; Guo, J.; Spergel, S. H.; Das, J.; Moquin, R. V.; Dyckman, A. J.; Nirschl, D.; Gregor, K.; Pattoli, M. A.; Yang, X.; McIntyre, K. W.; Yang, G.; Galella, M. A.; Booth-Lute, H.; Chen, L.; Yang, Z.; Wang-Iverson, D.; McKinnon, M.; Dodd, J. H.; Barrish, J. C.; Burke, J. R.; Pitts, W. J. Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1, 6-dihydroimidazo[4, 5-d]pyrrolo[2, 3-b] pyridin-7-yl) pyridin-2-yl) methyl) acetamide (BMS-066). Bioorg. Med. Chem. Lett., 2011, 21(23), 7006-7012.
84. Crombie, A. L.; Sum, F. W.; Powell, D. W.; Hopper, D. W.; Torres, N.; Berger, D. M.; Zhang, Y.; Gavriil, M.; Sadler, T. M.; Arndt, K. Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKbeta inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(12), 3821-3825.
85. Hideyuki Sugiyama, M. Y., Kouji Mori, Tomohiro Kawamoto, Satoshi Sogabe,; Terufumi Takagi, H. O. Toshimasa Tanaka, Hiroyuki Kimura, and Yoshinori IKEURA, Synthesis and Structure Activity Relationship Studies of Benzothieno[3, 2-b]furan Derivatives as a Novel Class of IKKb b Inhibitors. Chem. Pharm. Bull., 2007, 55 (4).
86. Li, J.; Li, X.; Catron, K. M. IKKalpha and IKKbeta specific inhibitors. US2012088298, 2012.
87. Karin, M.; Di Donato, J. A.; Rothwarf, D. M.; Hayakawa, M.; Zandi, E. IαB kinase, subunits thereof, and methods of using same. US20100055714, 2010.
88. Traincard, F.; Agou, F.; Veron, M. Identification of substances that inhibit NEMO oligomerization. US20090269748, 2009.
89. Agou, F.; Courtois, G.; Chiaravalli, J.; Baleux, F.; Coic, Y.; Traincard, F. Inhibition of NF-αB activation by peptides targeting NF-αB essential modulator (NEMO) oligomerization. J. Biochem., 2004, 279, 54248-54257.
90. Gamble, C.; McIntosh, K.; Scott, R.; Ho, K. H.; Plevin, R.; Paul, A. Inhibitory kappa B Kinases as targets for pharmacological regulation. Br. J. Pharmacol., 2012, 165(4), 802-819.
91. D., R. P.; J., N. L. Inhibiting the signs of aging by inhibiting NFkappa B activation. WO2008148016, 2008.
92. Brian, P.; Sankar, G. Mehtod of preventing development of psoriatic lesions. WO2012154684, 2012.
93. Golden, M. S.; Cote, S. M.; Sayeg, M.; Zerbe, B. S.; Villar, E. A.; Beglov, D.; Sazinsky, S. L.; Georgiadis, R. M.; Vajda, S.; Kozakov, D.; Whitty, A. Comprehensive Experimental and Computational Analysis of Binding Energy Hot Spots at the NF-kappaB Essential Modulator/IKKbeta Protein-Protein Interface. J. Am. Chem. Soc., 2013, 135(16), 6242-6256.
94. Mondal, S.; Roy, A.; Jana, A.; Ghosh, S.; Kordower, J. H.; Pahan, K. Testing NF-αB-based therapy in hemiparkinsonian monkeys. J. Neuroimmune Pharm., 2012, 7(3), 544-556.
95. Ghosh, A.; Roy, A.; Liu, X.; Kordower, J. H.; Mufson, E. J.; Hartley, D. M.; Ghosh, S.; Mosley, R. L.; Gendelman, H. E.; Pahan, K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2007, 104(47), 18754-18759.
96. Shah, A.; Verma, A. S.; Patel, K. H.; Noel, R.; Rivera-Amill, V.; Silverstein, P. S.; Chaudhary, S.; Bhat, H. K.; Stamatatos, L.; Singh, D. P.; Buch, S.; Kumar, A. HIV-1 gp120 Induces Expression of IL-6 through a Nuclear Factor-Kappa B-Dependent Mechanism: Suppression by gp120 Specific Small Interfering RNA. PloS One, 2011, 6(6), e21261.
97. Liu, S.; Misquitta, Y. R.; Olland, A.; Johnson, M. A.; Kelleher, K. S.; Kriz, R.; Lin, L. L.; Stahl, M.; Mosyak, L. Crystal Structure of A Human IkappaB Kinase beta Asymmetric Dimer. J. Biol. Chem., 2013, 288(31), 22758-22767.
98. Long, W.; Liu, P.; Li, X.; Xu, Y.; Yu, J.; Ma, S.; Yu, L.; Zou, Z. QSAR studies on imidazothienopyrazines as IKK-βinhibitors: from 2D to 3D. J. Chemom., 2009, 23(6), 304-314.
99. Nagarajan, S.; Doddareddy, M.r.; Choo, H.; Cho, Y. S.; Oh, K.-S.; Lee, B. H.; Pae, A. N. IKKβ inhibitors identification part I: Homology model assisted structure based virtual screening. Bioorg. Med. Chem., 2009, 17(7), 2759-2766.
100. Sala, E.; Guasch, L.; Iwaszkiewicz, J.; Mulero, M.; Salvadó, M.-J.; Pinent, M.; Zoete, V.; Grosdidier, A.; Garcia-Vallvé, S.; Michielin, O.; Pujadas, G. Identification of Human IKK-2 Inhibitors of Natural Origin (Part I): Modeling of the IKK-2 Kinase Domain, Virtual Screening and Activity Assays. PLoS One, 2011, 6(2), e16903.
101. Garber, K. The second wave in kinase cancer drugs. Nat. Biotechnol., nol., 2006, 24(2), 127-130.